Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 8/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9949115 | 0.84 | OPRL1 (0.50) | OPRL1OPRM1OPRD1OPRK1TSHR | |
| SCHEMBL23041363 | 0.77 | SLC6A9 (0.47) | OPRL1OPRM1OPRD1OPRK1TSHR | |
| SCHEMBL9234226 | 0.76 | OPRM1 (0.34) | OPRL1OPRM1HSD17B10 | |
| SCHEMBL3647086 | 0.75 | LTA4H (0.61) | OPRL1OPRM1OPRD1OPRK1TSHR | |
| SCHEMBL9029374 | 0.75 | OPRL1 (0.70) | OPRL1OPRM1OPRD1OPRK1CHRM2 | |
| SCHEMBL9948790 | 0.74 | HSD17B10 (0.43) | HSD17B10CYP2D6 | |
| SCHEMBL10940285 | 0.74 | ALDH1A1 (0.37) | TSHRALDH1A1CYP2D6CHRM2L3MBTL1 | |
| SCHEMBL6615174 | 0.74 | OPRL1 (0.61) | OPRL1OPRM1OPRD1OPRK1TSHR | |
| SCHEMBL7847623 | 0.74 | OPRL1 (1.00) | OPRL1OPRM1OPRD1OPRK1CHRM2 | |
| SCHEMBL9948876 | 0.73 | OPRL1 (0.53) | OPRL1OPRM1OPRD1OPRK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012101487-A1 | DI/TRI-AZA-SPIRO-C9-C11ALKANES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | TACR2, TACR1, AGTR1 | OPRL1 759/4885OPRM1 254/4885OPRD1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.